Tuan Vu, MD, Professor of Neurology at the University of South Florida, discusses positive results in Vivacity-MG3 study evaulating the safety and efficacy of nipocalimab for myasthenia gravis (MG).
MG is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. The condition results from a defect in the transmission of nerve impulses to muscles, which is due to the presence of antibodies against the acetylcholine receptors. The exact reason this occurs is not known. Weakness tends to increase during periods of activity and improve after periods of rest. Common symptoms include weakness of the muscles that control:
- Eye and eyelid
- Facial expressions
- Chewing
- Talking
- Swallowing
Nipocalimab is a fully human monoclonal antibody targeted at FcRn, a protein that attenuates the degradation of circulating IgG. By blocking FcRn activity, the net result is a reduction in circulating IgG antibody levels and thereby reducing the autoimmune pathophysiology that causes MG.
Vivacity-MG3
The Vivacity-MG3 study is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial further evaluating the efficacy and tolerability of nipocalimab. 153 adults with generalized MG who had an inadequate response to standard of care treatment were enrolled. The primary endpoint of this study was improvement in MG Activities of Daily Life (MG-ADL) score with Quantitative Myasthenia Gravis (QMG) score. Key secondary endpoints included MG-ADL responder rates, or the percentage of patients with a 2 or greater point improvement on average in MG-ADL scores.
Results include a statistically significant improvement in MG-ADL and QMG scores from baseline versus placebo with an average change of -4.7. MG-ADL responder rate was 68.8% in the nipocalimab group compared to the 52.6% in the placebo group. Additionally, the nipocalimab group saw greater sustained response to the treatment with 46.8% demonstrating a 50% or greater improvement in MG-ADL, versus 25% in the placebo group.
Overall, nipocalimab illustrated positive efficacy and safety in a broad population of MG patients.
For more information, click here.
To learn more about MG and other rare autoimmune conditions, visit https://checkrare.com/diseases/autoimmune-auto-inflammatory-disorders/
